What is the Org number of Natumin Pharma AB?

Natumin Pharma AB is registered with Bolagsverket / SCB under Org 5564747748.

What is the revenue of Natumin Pharma AB?

Natumin Pharma AB reported revenue of SEK 67,1M in 2024.

Natumin Pharma AB employs 24 people as of the latest annual report.

Stig Rikard Westrin is the CEO of Natumin Pharma AB, in role since 2022.

Marcus Erik Johan Stenkil chairs the board of Natumin Pharma AB, in role since 2025.

Natumin Pharma AB's registered address is Snickaregatan 10.

ABActive

Org 5564747748Snickaregatan 10, 566 33 HaboManufacture of perfume and toilet preparations· NACE 2042Est. 1993 · 32 years old24 employees

Actively employed in the business

Name	Role	Member since
Current (2)
SR Stig Rikard Westrin Chief Executive Officer	Chief Executive Officer	2022
SC Sandra Clara Ellen Hvitman Chief Auditor	Chief Auditor	2022
Former (4)
SK Sara Kristina Wulff External Signatory	External Signatory	2021 – 2022
BM Bo Magnus Lagerberg Chief Auditor	Chief Auditor	2020 – 2020
BC Bengt Claes Joakim Falck Chief Auditor	Chief Auditor	2023 – 2023
PM Paul Martin Kreutz External Signatory	External Signatory	2021 – 2022

Non-executive oversight

Name	Role	Member since
Current (3)
NC Noel Christofer Peter Abdayem Board of Directors	Board of Directors	2022
ME Marcus Erik Johan Stenkil Chairman	Chairman	2025
JC Johan Christer Lennartsson Board of Directors	Board of Directors	2022
Former (6)
KL Kjell Lundgren Deputy Board Member	Deputy Board Member	2020 – 2022
EM Emil Mikael Svahn Board of Directors	Board of Directors	2020 – 2022
SG Simon Gustav Seved Petrén Chairman	Chairman	2022 – 2025
UA Ulrika Ann-Britt Albers Chairman	Chairman	2020 – 2021
BP Bengt Peter Carlsson Board of Directors	Board of Directors	2022 – 2022
JP Jan Peter Hencz Chairman	Chairman	2021 – 2022

As of last annual report

Shareholder	Type	Ownership	Votes	Since
Nya MedicaNatumin AB	Company	100%	100%	2023

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.